Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:prostaglandin E2
go back to main search page
Accession:CHEBI:15551 term browser browse the term
Definition:Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.
Synonyms:exact_synonym: (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
 related_synonym: (15S)-prostaglandin E2;   (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid;   (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate;   (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate;   (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid;   (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid;   Dinoproston;   Dinoprostone;   Formula=C20H32O5;   InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1;   InChIKey=XEYBRNLFEZDVAW-ARSRFYASSA-N;   PGE2;   Prepidil;   Propess;   Prostin E2;   SMILES=CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1C\\C=C/CCCC(O)=O;   dinoprostona;   dinoprostonum
 alt_id: CHEBI:10910;   CHEBI:10911;   CHEBI:114125;   CHEBI:26323;   CHEBI:4625;   CHEBI:8512
 xref: Beilstein:2224724;   CAS:363-24-6;   DrugBank:DB00917;   Drug_Central:913;   HMDB:HMDB0001220;   KEGG:C00584;   KEGG:D00079;   LIPID_MAPS_instance:LMFA03010003
 xref_mesh: MESH:D015232
 xref: MetaCyc:5Z13E-15S-1115-DIHYDROXY-9-OXOPROS;   PMID:24501112;   PMID:7224729;   PMID:7836930;   Patent:DE2011969;   Patent:GB851827;   Patent:NL6505799;   Patent:US3598858;   Reaxys:2224724;   Wikipedia:Prostaglandin_E2
 cyclic_relationship: is_conjugate_acid_of CHEBI:606564


show annotations for term's descendants           Sort by:
 
prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc4 ATP binding cassette subfamily C member 4 increases export
affects export
ISO ABCC4 protein results in increased export of Dinoprostone
ABCC4 gene SNP affects the export of Dinoprostone
CTD PMID:22155354, PMID:27659809 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO ACE inhibits the reaction [Cocaine affects the abundance of Dinoprostone] CTD PMID:14738173 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Acta1 actin, alpha 1, skeletal muscle multiple interactions
decreases expression
EXP 4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid inhibits the reaction [Dinoprostone results in decreased expression of ACTA1 mRNA] CTD PMID:18030065 NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression ISO Dinoprostone results in increased expression of ACTA2 protein CTD PMID:27697457 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 multiple interactions EXP Dinoprostone inhibits the reaction [ADCYAP1 protein results in increased secretion of Histamine] CTD PMID:11164953 NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
JBrowse link
G Adm adrenomedullin decreases expression ISO Dinoprostone results in decreased expression of ADM mRNA CTD PMID:19253104 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions ISO [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone] CTD PMID:17369603 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Agt angiotensinogen multiple interactions
increases abundance
EXP Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of Dinoprostone] CTD PMID:4030047, PMID:6421564 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions ISO [sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; [zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased secretion of Dinoprostone] CTD PMID:21334316 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
ISO
EXP
Dinoprostone results in increased phosphorylation of AKT1 protein
taiwanin C inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]
Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]
Dinoprostone results in increased phosphorylation of and results in increased activity of AKT1 protein
CTD PMID:16396944, PMID:17805209, PMID:23747687, PMID:25094029, PMID:30884126 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alox15 arachidonate 15-lipoxygenase multiple interactions ISO [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone CTD PMID:21193584 NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
JBrowse link
G Anxa1 annexin A1 multiple interactions ISO ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone] CTD PMID:21777521 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions EXP Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of APOA1 mRNA] CTD PMID:15816358 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G App amyloid beta precursor protein increases abundance
multiple interactions
increases expression
EXP
ISO
APP protein modified form results in increased abundance of Dinoprostone
[APP protein binds to APP protein binds to APP protein] which results in increased abundance of Dinoprostone; neoechinulin A inhibits the reaction [[APP protein binds to APP protein binds to APP protein] which results in increased abundance of Dinoprostone]
PTGES2 promotes the reaction [APP protein modified form results in increased abundance of Dinoprostone]; resveratrol inhibits the reaction [APP protein results in increased secretion of Dinoprostone]
Dinoprostone results in increased expression of APP protein modified form
CTD PMID:16685418, PMID:20171164, PMID:23261590 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Aqp1 aquaporin 1 increases response to substance ISO AQP1 results in increased susceptibility to Dinoprostone CTD PMID:20018876 NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
JBrowse link
G Areg amphiregulin increases expression
multiple interactions
ISO
EXP
Dinoprostone results in increased expression of AREG mRNA; Dinoprostone results in increased expression of AREG protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]; U 0126 inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]
CTD PMID:15284208, PMID:15509566, PMID:16888076 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Atf1 activating transcription factor 1 multiple interactions
increases phosphorylation
ISO [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]]; Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein] CTD PMID:12164941, PMID:22188298 NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
JBrowse link
G Atf3 activating transcription factor 3 increases expression
multiple interactions
ISO Dinoprostone results in increased expression of ATF3 protein
ATF3 protein affects the reaction [Dinoprostone results in decreased expression of SIRT1 mRNA]; ATF3 protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Dinoprostone promotes the reaction [ATF3 protein binds to SIRT1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of ATF3 protein]
CTD PMID:30409902 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Avp arginine vasopressin increases abundance
multiple interactions
EXP AVP protein results in increased abundance of Dinoprostone
Dexamethasone inhibits the reaction [AVP protein results in increased abundance of Dinoprostone]
CTD PMID:4030047 NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BAK1 protein]] CTD PMID:25432964 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP
[BAX binds to Dinoprostone] which results in increased localization of BAX
Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BAX protein]
CTD PMID:16396944, PMID:17369862 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
ISO Dinoprostone results in increased expression of BCL2 protein
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]]
CTD PMID:9443418, PMID:25432964 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions EXP Dinoprostone affects the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] CTD PMID:16396944 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 increases expression ISO Dinoprostone results in increased expression of BIRC3 protein CTD PMID:12837940 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased expression of BIRC5 protein] CTD PMID:21268125 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions EXP [KNG1 protein co-treated with Dinoprostone] results in increased secretion of CALCA protein; Dinoprostone inhibits the reaction [Flurbiprofen inhibits the reaction [Histamine results in increased secretion of CALCA protein]]; Dinoprostone inhibits the reaction [Flurbiprofen inhibits the reaction [Serotonin results in increased secretion of CALCA protein]]; Dinoprostone promotes the reaction [Capsaicin results in increased secretion of CALCA protein]; Dinoprostone promotes the reaction [Protons results in increased secretion of CALCA protein] CTD PMID:11166334, PMID:12044622, PMID:14991081, PMID:18296611 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Casp3 caspase 3 decreases activity
multiple interactions
ISO
EXP
Dinoprostone results in decreased activity of CASP3 protein
Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]
Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein]
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; Dinoprostone inhibits the reaction [SIRT1 mutant form promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]]
CTD PMID:12837940, PMID:16396944, PMID:20335659, PMID:25094029, PMID:25432964 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP8 protein]] CTD PMID:25432964 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions ISO Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein] CTD PMID:25094029 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions
decreases abundance
EXP
ISO
CAT protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]]
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [CAT protein results in decreased abundance of Dinoprostone]
CTD PMID:10899936, PMID:11286988, PMID:25432964 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbs cystathionine beta synthase multiple interactions ISO CBS protein inhibits the reaction [Rotenone results in increased abundance of Dinoprostone] CTD PMID:25086357 NCBI chr20:10,361,987...10,386,663
Ensembl chr20:10,361,988...10,386,751
JBrowse link
G Ccl12 chemokine (C-C motif) ligand 12 multiple interactions ISO [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of CCL12 mRNA] CTD PMID:28434932 NCBI chr10:69,476,866...69,478,416
Ensembl chr10:69,476,775...69,478,462
JBrowse link
G Ccl17 C-C motif chemokine ligand 17 increases expression ISO Dinoprostone results in increased expression of CCL17 mRNA CTD PMID:16303787 NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
decreases expression
ISO Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of CCL2 protein]]
Dinoprostone results in decreased expression of CCL2 mRNA
CTD PMID:16303787, PMID:16784723, PMID:21913898, PMID:25432964 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions ISO [Dinoprostone co-treated with IL1B] results in increased expression of CCL20; Dinoprostone promotes the reaction [IL23A results in increased expression of CCL20]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20]
Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL20 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL20 protein]
CTD PMID:17667525, PMID:19273625 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Ccl22 C-C motif chemokine ligand 22 increases expression ISO Dinoprostone results in increased expression of CCL22 mRNA CTD PMID:16303787 NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
JBrowse link
G Ccl27 C-C motif chemokine ligand 27 multiple interactions ISO Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]] CTD PMID:16784723 NCBI chr 5:58,159,066...58,166,182
Ensembl chr 5:58,159,066...58,163,584
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions
decreases expression
ISO Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]
Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL3 protein]
Dinoprostone results in decreased expression of CCL3 mRNA
CTD PMID:9863660, PMID:16303787, PMID:17667525, PMID:21913898 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 decreases expression
multiple interactions
ISO Dinoprostone results in decreased expression of CCL4 protein
Dinoprostone results in decreased expression of CCL4 mRNA
Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]
CTD PMID:16303787, PMID:17667525, PMID:21913898 NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 decreases expression
multiple interactions
ISO Dinoprostone results in decreased expression of CCL5 mRNA
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]
Dinoprostone inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL5 protein]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]
CTD PMID:10495789, PMID:16303787, PMID:16784723, PMID:17667525 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA] CTD PMID:28434932 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO taiwanin C inhibits the reaction [Dinoprostone results in increased expression of CCND1 protein] CTD PMID:30884126 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccr5 C-C motif chemokine receptor 5 decreases expression ISO Dinoprostone results in decreased expression of CCR5 mRNA; Dinoprostone results in decreased expression of CCR5 protein CTD PMID:16303787 NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
JBrowse link
G Ccr6 C-C motif chemokine receptor 6 multiple interactions ISO [Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6 CTD PMID:19273625 NCBI chr 1:53,063,380...53,087,519
Ensembl chr 1:53,065,025...53,087,474
JBrowse link
G Ccr7 C-C motif chemokine receptor 7 increases expression
multiple interactions
ISO Dinoprostone results in increased expression of CCR7 mRNA; Dinoprostone results in increased expression of CCR7 protein
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein
CTD PMID:16303787, PMID:18952292 NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
JBrowse link
G Cd68 Cd68 molecule multiple interactions ISO Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of CD68 protein] CTD PMID:25432964 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
JBrowse link
G Cdh1 cadherin 1 decreases expression
multiple interactions
ISO Dinoprostone results in decreased expression of CDH1 protein
cryptotanshinone inhibits the reaction [Dinoprostone results in decreased expression of CDH1 protein]
CTD PMID:30208247 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CEBPA protein]] CTD PMID:25432964 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cga glycoprotein hormones, alpha polypeptide multiple interactions
increases secretion
EXP
ISO
bifenthrin analog inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; bifenthrin inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]
butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; Dibutyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; Diethylhexyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]
CTD PMID:21251947, PMID:21871944, PMID:25016925 NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
JBrowse link
G Col10a1 collagen type X alpha 1 chain increases expression ISO Dinoprostone results in increased expression of COL10A1 mRNA; Dinoprostone results in increased expression of COL10A1 protein CTD PMID:27050768 NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression ISO Dinoprostone results in decreased expression of COL1A1 mRNA CTD PMID:8971655 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col2a1 collagen type II alpha 1 chain increases expression ISO Dinoprostone results in increased expression of COL2A1 mRNA; Dinoprostone results in increased expression of COL2A1 protein CTD PMID:27050768 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
G Cp ceruloplasmin increases secretion EXP CP protein results in increased secretion of Dinoprostone CTD PMID:17727827 NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
increases phosphorylation
ISO [nickel sulfate co-treated with Dinoprostone] results in increased expression of CREB1 protein; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; CREB1 protein promotes the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased secretion of CXCL8 protein]; Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein] CTD PMID:12164941, PMID:23526216 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Cryab crystallin, alpha B multiple interactions EXP Dinoprostone promotes the reaction [arsenite results in increased expression of CRYAB mRNA]; Dinoprostone promotes the reaction [arsenite results in increased expression of CRYAB protein] CTD PMID:9066782 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]]
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein
CTD PMID:15180965, PMID:18952292 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ctnnb1 catenin beta 1 increases localization
increases expression
multiple interactions
ISO Dinoprostone results in increased localization of CTNNB1 protein
Dinoprostone results in increased expression of CTNNB1 protein
cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of CTNNB1 protein]
CTD PMID:18395713, PMID:30208247 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]] CTD PMID:21913898 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 increases expression ISO Dinoprostone results in increased expression of CXCR4 mRNA; Dinoprostone results in increased expression of CXCR4 protein CTD PMID:16303787 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression ISO Dinoprostone results in increased expression of CYP11A1 mRNA CTD PMID:19001523 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 increases expression ISO Dinoprostone results in increased expression of CYP17A1 mRNA CTD PMID:19001523 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions
increases activity
increases expression
ISO
EXP
2-methoxyoestrone-3-O-sulphamate inhibits the reaction [Dinoprostone results in increased activity of CYP19A1 protein]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ATF3 protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; bakuchiol inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; Chlordan inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; Chlordan inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Dinoprostone inhibits the reaction [NR2F2 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 mRNA]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 protein]; Dinoprostone promotes the reaction [NR5A1 protein binds to CYP19A1 promoter]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Resveratrol inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]
Dinoprostone results in increased expression of CYP19A1 mRNA; Dinoprostone results in increased expression of CYP19A1 protein
CTD PMID:15862962, PMID:16024248, PMID:19001523, PMID:20351196, PMID:20678559, PMID:23054057, PMID:28571770, PMID:30409902, PMID:31238046 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions
increases expression
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; fulvestrant inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; fulvestrant inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]
Dinoprostone results in increased expression of CYP1B1 mRNA; Dinoprostone results in increased expression of CYP1B1 protein
CTD PMID:20093341 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO Dinoprostone promotes the reaction [DDIT3 protein binds to CXCL8 promoter] CTD PMID:17709599 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]] CTD PMID:21911040 NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
JBrowse link
G Edn1 endothelin 1 multiple interactions
increases secretion
EXP
ISO
[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]
EDN1 protein results in increased secretion of Dinoprostone
CTD PMID:16384872, PMID:21811393 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Egf epidermal growth factor multiple interactions
increases abundance
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]] CTD PMID:17805209 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor increases secretion
increases expression
multiple interactions
increases phosphorylation
ISO EGFR protein results in increased secretion of Dinoprostone
Dinoprostone results in increased expression of EGFR protein modified form
cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of EGFR protein modified form]; EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; EGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone]
Dinoprostone results in increased phosphorylation of EGFR protein
CTD PMID:16213893, PMID:17805209, PMID:20850495, PMID:30208247 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Ep300 E1A binding protein p300 multiple interactions ISO Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]] CTD PMID:30409902 NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
JBrowse link
G Ephx2 epoxide hydrolase 2 multiple interactions ISO EPHX2 gene mutant form affects the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]; EPHX2 gene mutant form promotes the reaction [Aspirin inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]] CTD PMID:19896470 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Ereg epiregulin increases expression
multiple interactions
ISO Dinoprostone results in increased expression of EREG mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA]; U 0126 inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA]
CTD PMID:16888076, PMID:18444251 NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
JBrowse link
G Esr1 estrogen receptor 1 increases phosphorylation ISO Dinoprostone results in increased phosphorylation of ESR1 protein CTD PMID:20093341 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esrra estrogen related receptor, alpha multiple interactions
increases expression
ISO 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of ESRRA mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of ESRRA protein]; Dinoprostone promotes the reaction [ESRRA protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein promotes the reaction [Testosterone results in increased abundance of Estradiol]]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 mRNA]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 protein]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 protein]
Dinoprostone results in increased expression of ESRRA mRNA; Dinoprostone results in increased expression of ESRRA protein
CTD PMID:20351196 NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
JBrowse link
G F2 coagulation factor II multiple interactions
increases secretion
EXP
ISO
[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]
tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]]
CTD PMID:21811393, PMID:26385185 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link
G Fas Fas cell surface death receptor increases expression
decreases expression
ISO Dinoprostone results in increased expression of FAS
Dinoprostone results in decreased expression of FAS mRNA
CTD PMID:10357836, PMID:15491851 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand increases expression
multiple interactions
increases response to substance
ISO Dinoprostone results in increased expression of FASLG
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of FASL protein]]
FASLG results in increased susceptibility to Dinoprostone
CTD PMID:15491851, PMID:25432964 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO Dinoprostone promotes the reaction [Celecoxib results in decreased activity of FASN protein] CTD PMID:19159447 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fcer2 Fc fragment of IgE receptor II decreases expression ISO Dinoprostone results in decreased expression of FCER2 protein CTD PMID:1328389 NCBI chr12:2,233,772...2,245,324
Ensembl chr12:2,233,778...2,245,324
JBrowse link
G Fgf20 fibroblast growth factor 20 increases abundance ISO FGF20 protein results in increased abundance of Dinoprostone CTD PMID:12360478 NCBI chr16:55,152,748...55,159,352
Ensembl chr16:55,152,748...55,159,352
JBrowse link
G Fgf23 fibroblast growth factor 23 multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone]; FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone; SB 203580 inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone] CTD PMID:16144964 NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
JBrowse link
G Fgf7 fibroblast growth factor 7 increases secretion
multiple interactions
EXP FGF7 protein results in increased secretion of Dinoprostone
Indomethacin inhibits the reaction [FGF7 protein results in increased secretion of Dinoprostone]
CTD PMID:16169897 NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression ISO Dinoprostone results in increased expression of FOS mRNA CTD PMID:10864209 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gast gastrin multiple interactions EXP Dinoprostone inhibits the reaction [GAST protein results in increased secretion of Histamine] CTD PMID:11164953 NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
JBrowse link
G Ghrl ghrelin and obestatin prepropeptide increases abundance EXP GHRL results in increased abundance of Dinoprostone CTD PMID:16868036 NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
JBrowse link
G Glra3 glycine receptor, alpha 3 multiple interactions
increases response to substance
ISO Dinoprostone inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of [PTGER2 protein co-treated with GLRA3 protein]]
GLRA3 results in increased susceptibility to Dinoprostone
CTD PMID:15131310 NCBI chr16:37,676,959...37,908,221
Ensembl chr16:37,676,962...38,063,821
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO Dinoprostone inhibits the reaction [Acetaminophen results in increased expression of GPT protein] CTD PMID:31444509 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions ISO Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of GPX1 mRNA]] CTD PMID:25432964 NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions
affects secretion
ISO [GPX2 protein affects the activity of PTGS2 protein] which affects the metabolism of Dinoprostone; [GPX2 protein affects the expression of PTGES protein] which affects the metabolism of Dinoprostone
GPX2 protein affects the secretion of Dinoprostone
CTD PMID:18479189 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A increases response to substance ISO GRIN2A results in increased susceptibility to Dinoprostone CTD PMID:9113374 NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
JBrowse link
G Grin2d glutamate ionotropic receptor NMDA type subunit 2D increases response to substance ISO GRIN2D results in increased susceptibility to Dinoprostone CTD PMID:9113374 NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha increases phosphorylation ISO Dinoprostone results in increased phosphorylation of GSK3A protein CTD PMID:20578217 NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases phosphorylation
multiple interactions
decreases expression
ISO Dinoprostone results in increased phosphorylation of GSK3B protein
cryptotanshinone inhibits the reaction [Dinoprostone results in decreased expression of GSK3B protein]
CTD PMID:18395713, PMID:20578217, PMID:30208247 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gstm2 glutathione S-transferase mu 2 affects chemical synthesis ISO GSTM2 protein affects the chemical synthesis of Dinoprostone CTD PMID:10905636 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm3 glutathione S-transferase mu 3 affects chemical synthesis ISO GSTM3 protein affects the chemical synthesis of Dinoprostone CTD PMID:10905636 NCBI chr 2:210,685,204...210,688,273
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 affects chemical synthesis ISO GSTM3 protein affects the chemical synthesis of Dinoprostone CTD PMID:10905636 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions ISO [HCAR2 protein results in increased susceptibility to Niacin] which results in increased abundance of Dinoprostone CTD PMID:16322797 NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
JBrowse link
G Hcrt hypocretin neuropeptide precursor multiple interactions
increases abundance
EXP [HCRT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone
HCRT results in increased abundance of Dinoprostone
CTD PMID:18378017 NCBI chr10:88,669,216...88,670,430
Ensembl chr10:88,669,214...88,670,430
JBrowse link
G Hgf hepatocyte growth factor increases abundance EXP HGF protein results in increased abundance of Dinoprostone CTD PMID:14751415 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein; [nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]; Dinoprostone promotes the reaction [nickel sulfate results in increased expression of and results in increased activity of HIF1A protein]; Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein; HIF1A protein promotes the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased secretion of CXCL8 protein]; HIF1A protein promotes the reaction [[Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Resveratrol inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]
[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of HIF1A mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]
CTD PMID:18832182, PMID:20042640, PMID:20335389, PMID:23526216, PMID:28434932, PMID:30409902 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hk2 hexokinase 2 increases expression
multiple interactions
ISO Dinoprostone results in increased expression of HK2 mRNA
Dinoprostone promotes the reaction [nickel chloride results in increased expression of HK2 mRNA]
CTD PMID:27452194 NCBI chr 4:113,559,396...113,609,897
Ensembl chr 4:113,559,427...113,610,243
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO HMOX1 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]]
[chromium mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [N-bromotaurine results in decreased abundance of Dinoprostone]; [chromium mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [N-chlorotaurine results in decreased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [copper protoporphyrin IX promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Dinoprostone inhibits the reaction [KT 5720 promotes the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; HMOX1 protein inhibits the reaction [Dimethyl Fumarate inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; HMOX1 protein inhibits the reaction [Probucol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; HMOX1 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; KT 5720 inhibits the reaction [Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]
CTD PMID:18157587, PMID:19428335, PMID:22155307, PMID:23942037, PMID:24003391 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase affects abundance
multiple interactions
increases metabolic processing
ISO HPGD protein affects the abundance of Dinoprostone
[Dinoprostone co-treated with NAD] binds to HPGD protein
HPGD protein results in increased metabolism of Dinoprostone
CTD PMID:18500342, PMID:19584167, PMID:20448048, PMID:25526675 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hrh2 histamine receptor H 2 multiple interactions ISO Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] CTD PMID:9187264 NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases activity
ISO 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased activity of HSD11B1 protein]; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein]; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; PTGER2 protein promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein] CTD PMID:17761898 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 decreases activity ISO Dinoprostone results in decreased activity of HSD11B2 protein CTD PMID:10377029 NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression ISO Dinoprostone results in increased expression of HSD3B2 mRNA CTD PMID:19001523 NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression
ISO Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]]; Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]]; Dinoprostone inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
Dinoprostone results in increased expression of ICAM1 mRNA; Dinoprostone results in increased expression of ICAM1 protein
CTD PMID:10495789, PMID:16777358 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ifng interferon gamma multiple interactions
increases abundance
decreases expression
ISO
EXP
2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; carnosol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; Dimethyl Fumarate inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; NFE2L2 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; Probucol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; sulforafan inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]
Dinoprostone results in decreased expression of IFNG protein
[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; Indomethacin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; nimesulide inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; sulforafan inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]
CTD PMID:9743329, PMID:12911628, PMID:14623498, PMID:15177302, PMID:15788148, PMID:16716910, PMID:19071154, PMID:23362215, PMID:23942037 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Ighe immunoglobulin heavy constant epsilon increases expression ISO Dinoprostone results in increased expression of IGHE protein CTD PMID:15788148 NCBI chr 6:138,066,728...138,068,606 JBrowse link
G Il10 interleukin 10 decreases expression
increases abundance
decreases abundance
multiple interactions
ISO Dinoprostone results in decreased expression of IL10; Dinoprostone results in decreased expression of IL10 protein
IL10 protein results in increased abundance of Dinoprostone
IL10 protein results in decreased abundance of Dinoprostone
Dinoprostone promotes the reaction [Zymosan results in increased expression of IL10 mRNA]; Dinoprostone promotes the reaction [Zymosan results in increased expression of IL10 protein]; IL10 gene mutant form promotes the reaction [Silicon Dioxide results in increased abundance of Dinoprostone]
Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; IL10 protein inhibits the reaction [Endotoxins results in increased abundance of Dinoprostone]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]
CTD PMID:7582491, PMID:11301049, PMID:12548226, PMID:14975940, PMID:16303787, PMID:19273625 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il11 interleukin 11 multiple interactions
increases abundance
ISO Flurbiprofen inhibits the reaction [IL11 protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL11 protein results in increased abundance of Dinoprostone] CTD PMID:12110441 NCBI chr 1:72,636,959...72,643,255
Ensembl chr 1:72,635,267...72,643,255
JBrowse link
G Il12a interleukin 12A multiple interactions ISO Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]] CTD PMID:11369638 NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression
increases secretion
ISO [TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]
Dinoprostone results in increased expression of IL12B protein
CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]]; Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]
Dinoprostone results in increased secretion of IL12B protein
Dinoprostone results in increased expression of IL12B mRNA; Dinoprostone results in increased expression of IL12B protein
CTD PMID:10614771, PMID:11369638, PMID:15180965, PMID:16303787 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il12rb1 interleukin 12 receptor subunit beta 1 decreases expression ISO Dinoprostone results in decreased expression of IL12RB1 protein CTD PMID:9743329 NCBI chr16:20,370,722...20,383,576
Ensembl chr16:20,371,338...20,383,337
JBrowse link
G Il12rb2 interleukin 12 receptor subunit beta 2 decreases expression ISO Dinoprostone results in decreased expression of IL12RB2 mRNA CTD PMID:9743329 NCBI chr 4:98,049,195...98,141,562
Ensembl chr 4:98,052,842...98,141,482
JBrowse link
G Il13 interleukin 13 increases secretion ISO Dinoprostone results in increased secretion of IL13 protein CTD PMID:15788148 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
JBrowse link
G Il17f interleukin 17F multiple interactions ISO [Dinoprostone co-treated with IL23A] results in increased expression of IL17F; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [IL1B results in increased expression of IL17F] CTD PMID:19273625 NCBI chr 9:26,885,702...26,897,219
Ensembl chr 9:26,885,708...26,897,219
JBrowse link
G Il17ra interleukin 17 receptor A multiple interactions ISO IL17RA gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone] CTD PMID:22359662 NCBI chr 4:152,995,865...153,018,394
Ensembl chr 4:152,995,865...153,018,394
JBrowse link
G Il1a interleukin 1 alpha increases abundance
multiple interactions
increases secretion
ISO
EXP
IL1A protein results in increased abundance of Dinoprostone
mofezolac inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone]
[IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone
IL1A protein results in increased secretion of Dinoprostone
CTD PMID:8218930, PMID:11351503, PMID:15167967, PMID:16169897, PMID:21513769 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion
increases abundance
increases expression
increases chemical synthesis
ISO
EXP
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; 1-Butanol inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]]; [[Oligomycins co-treated with IL1B protein] results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6; [Dinoprostone co-treated with IL1B] results in increased expression of CCL20; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; [Triclosan co-treated with Cetylpyridinium] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Acetaminophen inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]]; Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; BAY 11-7085 inhibits the reaction [[IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone]; Butylated Hydroxyanisole inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Celecoxib promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; Celecoxib promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dactinomycin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dactinomycin inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dimethyl Sulfoxide inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [IL1B protein results in increased expression of NRG1 mRNA]]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone promotes the reaction [IL1B results in increased expression of IL17F]; Flurbiprofen inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; HMOX1 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; L 745337 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; licochalcone A inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Naproxen promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; Naproxen promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Oligomycins promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; prolinedithiocarbamate inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; PTGS1 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; PTGS2 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Quercetin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Ro 31-8220 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; rofecoxib promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; rofecoxib promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; sargachromanol G inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; sauchinone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; SC 560 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Tamoxifen promotes the reaction [Resveratrol inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]]; Triclosan inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]
Dinoprostone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]
IL1B protein results in increased abundance of Dinoprostone; IL1B results in increased abundance of Dinoprostone
[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]]; sulforafan inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]
2-methoxycinnamaldehyde inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Ketorolac co-treated with IL1B protein] results in increased secretion of Dinoprostone; CAT protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; cinnamic aldehyde inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Dinoprostone inhibits the reaction [IL1B protein results in increased abundance of copper bis(3,5-diisopropylsalicylate)]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; GW0072 inhibits the reaction [[IL1B protein co-treated with Rosiglitazone] results in increased secretion of Dinoprostone]; IL1B protein promotes the reaction [PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; IL1B protein promotes the reaction [Rosiglitazone results in increased secretion of Dinoprostone]; Indomethacin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrrolidine dithiocarbamic acid inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; sulforafan inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]
Dinoprostone results in increased expression of IL1B protein
CTD PMID:1515551, PMID:7582491, PMID:8662662, PMID:9266823, PMID:10614771, PMID:10800959, PMID:11112151, PMID:11229466, PMID:11286988, PMID:11530235, PMID:11854442, PMID:11882577, PMID:12512699, PMID:12517972, PMID:12548226, PMID:12681956, PMID:12743569, PMID:12897060, PMID:14623498, PMID:14762100, PMID:15144122, PMID:15180920, PMID:15180965, PMID:16253096, PMID:16354411, PMID:16357062, PMID:16492401, PMID:16529823, PMID:16624280, PMID:17077517, PMID:17605605, PMID:18026701, PMID:18054255, PMID:18759268, PMID:18952292, PMID:19071154, PMID:19273625, PMID:19428335, PMID:19751497, PMID:21878375, PMID:21954917, PMID:22039321, PMID:22089456, PMID:22155307, PMID:22549761, PMID:22592909, PMID:22727857, PMID:24609059, PMID:25432964, PMID:27645308, PMID:29356224, PMID:32061760 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases activity
increases expression
ISO Dinoprostone results in increased activity of IL1R1 protein
Dinoprostone results in increased expression of IL1R1 mRNA
CTD PMID:19273625, PMID:19407222 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Il1rn interleukin 1 receptor antagonist multiple interactions ISO Dinoprostone inhibits the reaction [IL1RN protein results in decreased expression of IL6 protein]; IL1RN protein inhibits the reaction [Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]] CTD PMID:8520508 NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
JBrowse link
G Il2 interleukin 2 decreases expression ISO Dinoprostone results in decreased expression of IL2; Dinoprostone results in decreased expression of IL2 protein CTD PMID:2948675, PMID:2989362 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il22 interleukin 22 decreases expression ISO Dinoprostone results in decreased expression of IL22 CTD PMID:19273625 NCBI chr 7:61,236,037...61,240,502
Ensembl chr 7:61,236,037...61,240,502
JBrowse link
G Il23a interleukin 23 subunit alpha multiple interactions
increases expression
ISO [Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6; [Dinoprostone co-treated with IL23A] results in increased expression of IL17F; Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA]; Dinoprostone promotes the reaction [IL23A results in increased expression of CCL20]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20]
Dinoprostone results in increased expression of IL23A protein
CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]]; Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]
Dinoprostone results in increased expression of IL23A mRNA
CTD PMID:15180965, PMID:19273625 NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Dinoprostone results in decreased expression of IL2RA CTD PMID:2948675 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
JBrowse link
G Il2rg interleukin 2 receptor subunit gamma decreases expression ISO Dinoprostone results in decreased expression of IL2RG CTD PMID:19812686 NCBI chr  X:71,165,378...71,169,078
Ensembl chr  X:71,162,585...71,169,865
JBrowse link
G Il4 interleukin 4 increases secretion
multiple interactions
decreases secretion
increases response to substance
ISO Dinoprostone results in increased secretion of IL4 protein; IL4 protein results in increased secretion of Dinoprostone
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]
IL4 results in decreased secretion of Dinoprostone
IL4 protein results in increased susceptibility to Dinoprostone
CTD PMID:12370375, PMID:15788148, PMID:18952292, PMID:19767084, PMID:23688403 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il5 interleukin 5 increases secretion ISO Dinoprostone results in increased secretion of IL5 protein CTD PMID:15788148 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO
EXP
[Dinoprostone co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; Dinoprostone inhibits the reaction [IL1RN protein results in decreased expression of IL6 protein]; Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; IL1RN protein inhibits the reaction [Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]]
[IL6 protein results in increased expression of PTGES mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [IL6 protein results in increased expression of PTGS2 mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; Celecoxib inhibits the reaction [IL6 protein results in increased secretion of and results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; IL6 protein results in increased secretion of and results in increased abundance of Dinoprostone
Dinoprostone results in increased expression of IL6 protein
Dexamethasone inhibits the reaction [Dinoprostone results in increased expression of IL6 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Lipopolysaccharides promotes the reaction [Dinoprostone results in increased expression of IL6 protein]
CTD PMID:7536779, PMID:8520508, PMID:15180965, PMID:15379866, PMID:16303787, PMID:18952292, PMID:20388727, PMID:21803157, PMID:24285838, PMID:25432964 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Irak3 interleukin-1 receptor-associated kinase 3 increases expression ISO prostaglandin E2 increases expression of Irak3 protein in alveolar macrophages RGD PMID:20439918 RGD:36049799 NCBI chr 7:64,922,830...64,982,224
Ensembl chr 7:64,923,615...64,982,281
JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions ISO
EXP
ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]; TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]]
ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]
CTD PMID:18234883 NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
JBrowse link
G Itgb1 integrin subunit beta 1 increases response to substance EXP ITGB1 results in increased susceptibility to Dinoprostone CTD PMID:14984413 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO Dinoprostone results in decreased phosphorylation of and results in decreased activity of JAK3 protein CTD PMID:19812686 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Kat2b lysine acetyltransferase 2B multiple interactions ISO KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein] CTD PMID:30409902 NCBI chr 9:4,440,982...4,492,949 JBrowse link
G Kng2 kininogen 2 multiple interactions
increases abundance
increases secretion
EXP [KNG1 protein co-treated with Dinoprostone] results in increased secretion of CALCA protein; [KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; [KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone; [Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of Dinoprostone]; Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Dinoprostone promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]; Flurbiprofen inhibits the reaction [[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone]; Flurbiprofen inhibits the reaction [[Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; Serotonin promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Streptozocin promotes the reaction [KNG1 protein modified form results in increased secretion of Dinoprostone]
KNG1 protein alternative form results in increased abundance of Dinoprostone; KNG1 protein results in increased abundance of Dinoprostone
CTD PMID:4030047, PMID:11166334, PMID:12791437, PMID:18234883, PMID:20832942, PMID:21811393 NCBI chr11:81,509,185...81,516,759 JBrowse link
G Ldha lactate dehydrogenase A multiple interactions
increases expression
ISO Dinoprostone promotes the reaction [nickel chloride results in increased expression of LDHA mRNA]
Dinoprostone results in increased expression of LDHA mRNA
CTD PMID:27452194 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G Lep leptin increases abundance
increases secretion
increases expression
EXP LEP protein results in increased abundance of Dinoprostone
Dinoprostone results in increased secretion of LEP protein
Dinoprostone results in increased expression of LEP protein
CTD PMID:11060898, PMID:16015682 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 multiple interactions ISO MAP3K8 protein affects the reaction [arsenite results in increased secretion of Dinoprostone] CTD PMID:19808956 NCBI chr17:56,109,403...56,129,925
Ensembl chr17:56,109,549...56,129,919
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases activity
increases phosphorylation
multiple interactions
ISO
EXP
Dinoprostone results in increased activity of MAPK1 protein
Dinoprostone results in increased phosphorylation of MAPK1 protein
Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]
gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]
CTD PMID:16888076, PMID:17805209, PMID:18030065, PMID:19201774, PMID:25234201, PMID:26464283 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 increases activity
increases phosphorylation
multiple interactions
ISO
EXP
Dinoprostone results in increased activity of MAPK14 protein
Dinoprostone results in increased phosphorylation of MAPK14 protein
L-826266 inhibits the reaction [Dinoprostone results in increased activity of MAPK14 protein]
CTD PMID:16644903, PMID:18030065 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases activity
increases phosphorylation
multiple interactions
ISO
EXP
Dinoprostone results in increased activity of MAPK3 protein
Dinoprostone results in increased phosphorylation of MAPK3 protein
Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]
CTD PMID:16888076, PMID:17805209, PMID:18030065, PMID:19201774, PMID:25234201, PMID:26464283 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases activity
multiple interactions
ISO Dinoprostone results in increased activity of MAPK8 protein
L-826266 inhibits the reaction [Dinoprostone results in increased activity of MAPK8 protein]
CTD PMID:16644903 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein] CTD PMID:25094029 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of MMP3 mRNA]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] CTD PMID:28434932 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
increases secretion
ISO Dinoprostone results in increased expression of MMP9 mRNA; Dinoprostone results in increased expression of MMP9 protein
15-deoxyprostaglandin J2 inhibits the reaction [Dinoprostone results in increased expression of MMP9 mRNA]; 15-deoxyprostaglandin J2 inhibits the reaction [Dinoprostone results in increased secretion of MMP9 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; Fenofibrate inhibits the reaction [Dinoprostone results in increased expression of MMP9 mRNA]; Fenofibrate inhibits the reaction [Dinoprostone results in increased secretion of MMP9 protein]
CTD PMID:16330497, PMID:19880272, PMID:25094029 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] CTD PMID:22039321 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]] CTD PMID:22363816 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc1 mucin 1, cell surface associated multiple interactions ISO [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein CTD PMID:18952292 NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
decreases expression
ISO
EXP
Dinoprostone results in increased expression of MYC; Dinoprostone results in increased expression of MYC protein
Dinoprostone results in decreased expression of MYC
CTD PMID:1315190, PMID:8667251 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myh7 myosin heavy chain 7 increases expression
multiple interactions
EXP Dinoprostone results in increased expression of MYH7 protein
Colforsin inhibits the reaction [Dinoprostone results in increased expression of MYH7 protein]
CTD PMID:18851973 NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO NFE2L2 protein inhibits the reaction [Dimethyl Fumarate inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; NFE2L2 protein inhibits the reaction [Probucol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; NFE2L2 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; NFE2L2 protein promotes the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone] CTD PMID:23942037 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
affects activity
ISO [L-335677 co-treated with 6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with L-826266 co-treated with L-161982] inhibits the reaction [Dinoprostone affects the activity of NFKB1 protein] CTD PMID:18297109 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein]
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased degradation of and results in decreased expression of NFKBIA protein]]
CTD PMID:22188298, PMID:25432964 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Ngf nerve growth factor multiple interactions
increases secretion
EXP Acetaminophen affects the reaction [NGF protein results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [NGF protein results in increased secretion of Dinoprostone] CTD PMID:21811393 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases response to substance
ISO
EXP
[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Dinoprostone; honokiol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Dinoprostone]
Dinoprostone inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; Dinoprostone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]
NOS2 results in increased susceptibility to Dinoprostone
[Ozone results in increased expression of NOS2 protein] which results in increased abundance of Dinoprostone; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]
CTD PMID:11919077, PMID:15491851, PMID:16325209, PMID:16944022, PMID:21147091, PMID:25432964 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nppa natriuretic peptide A increases expression
multiple interactions
increases abundance
EXP Dinoprostone results in increased expression of NPPA mRNA; Dinoprostone results in increased expression of NPPA protein
Colforsin inhibits the reaction [Dinoprostone results in increased expression of NPPA protein]
NPPA protein results in increased abundance of Dinoprostone
CTD PMID:3070145, PMID:18030065, PMID:18851973 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nppb natriuretic peptide B increases expression EXP Dinoprostone results in increased expression of NPPB mRNA CTD PMID:18030065 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 multiple interactions ISO Dinoprostone inhibits the reaction [NR2F2 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [NR2F2 protein binds to STAR promoter] CTD PMID:19001523 NCBI chr 1:131,447,671...131,465,749
Ensembl chr 1:131,448,447...131,460,473
JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 increases expression
multiple interactions
ISO Dinoprostone results in increased expression of NR4A2
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]
CTD PMID:16293616, PMID:22188298 NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO Dinoprostone promotes the reaction [NR5A1 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [NR5A1 protein binds to STAR promoter] CTD PMID:19001523 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
JBrowse link
G Nrg1 neuregulin 1 multiple interactions
increases expression
ISO Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [IL1B protein results in increased expression of NRG1 mRNA]]
Dinoprostone results in increased expression of NRG1 mRNA
CTD PMID:16357062 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Orm1 orosomucoid 1 multiple interactions EXP Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of ORM1 mRNA] CTD PMID:15816358 NCBI chr 5:79,179,668...79,182,820
Ensembl chr 5:79,179,417...79,182,820
JBrowse link
G Osmr oncostatin M receptor multiple interactions ISO Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of OSMR mRNA]] CTD PMID:25432964 NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
JBrowse link
G Park7 Parkinsonism associated deglycase multiple interactions ISO PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]] CTD PMID:26691871 NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO Dinoprostone inhibits the reaction [baohuoside I results in increased cleavage of PARP1 protein] CTD PMID:19289254 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdgfa platelet derived growth factor subunit A multiple interactions
increases abundance
ISO 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; Celecoxib inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; Ibuprofen inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PDGFA results in increased abundance of Dinoprostone] CTD PMID:19201774 NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
JBrowse link
G Pklr pyruvate kinase L/R decreases expression ISO Dinoprostone results in decreased expression of PKLR mRNA CTD PMID:10357836 NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
JBrowse link
G Pla2g2a phospholipase A2 group IIA increases expression ISO Dinoprostone results in increased expression of PLA2G2A protein CTD PMID:15964894 NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
JBrowse link
G Pla2g4a phospholipase A2 group IVA multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; [lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]
[Cadmium results in increased activity of PLA2G4A protein] which results in increased abundance of Dinoprostone
CTD PMID:15212812, PMID:15878913, PMID:20850495 NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
JBrowse link
G Pla2g5 phospholipase A2, group V multiple interactions ISO PLA2G5 protein promotes the reaction [Zymosan results in increased metabolism of Dinoprostone] CTD PMID:14761945 NCBI chr 5:157,247,601...157,268,968
Ensembl chr 5:157,247,781...157,268,903
JBrowse link
G Pld1 phospholipase D1 multiple interactions ISO PLD1 protein promotes the reaction [cobaltous chloride results in increased abundance of Dinoprostone] CTD PMID:17640750 NCBI chr 2:113,651,967...113,849,403
Ensembl chr 2:113,652,348...113,849,403
JBrowse link
G Pld2 phospholipase D2 multiple interactions ISO PLD2 protein promotes the reaction [cobaltous chloride results in increased abundance of Dinoprostone] CTD PMID:17640750 NCBI chr10:57,161,921...57,181,148
Ensembl chr10:57,163,174...57,179,730
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO [[nimesulide results in decreased activity of PTGS2 protein] co-treated with [GW0742 binds to and results in increased activity of PPARD protein]] results in decreased abundance of Dinoprostone; PPARD protein affects the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; PPARD protein mutant form inhibits the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone] CTD PMID:19748995 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Ppp1r9b protein phosphatase 1, regulatory subunit 9B multiple interactions
decreases expression
increases expression
EXP fulvestrant inhibits the reaction [Dinoprostone results in decreased expression of PPP1R9B protein]; PTGER1 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER2 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER3 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER4 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein] CTD PMID:17408863, PMID:18726914, PMID:23054057 NCBI chr10:82,800,704...82,816,735
Ensembl chr10:82,800,704...82,816,731
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions ISO [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of PRKACA protein CTD PMID:22188298 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
JBrowse link
G Prkce protein kinase C, epsilon affects response to substance EXP PRKCE protein affects the susceptibility to Dinoprostone CTD PMID:18509033 NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
JBrowse link
G Prl prolactin multiple interactions ISO Dinoprostone promotes the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] CTD PMID:7506205 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Prodh1 proline dehydrogenase 1 multiple interactions ISO [PRODH results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone CTD PMID:18794809 NCBI chr11:87,058,478...87,075,785
Ensembl chr11:87,058,616...87,075,785
JBrowse link
G Psen2 presenilin 2 multiple interactions ISO [PSEN2 protein mutant form results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone CTD PMID:16331303 NCBI chr13:98,513,600...98,539,347
Ensembl chr13:98,513,570...98,530,724
JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO Dinoprostone binds to and results in increased activity of PTGDR protein; Dinoprostone inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725, PMID:27636113 NCBI chr15:19,195,606...19,196,508 JBrowse link
G Ptger1 prostaglandin E receptor 1 increases response to substance
multiple interactions
increases activity
ISO
EXP
PTGER1 protein results in increased susceptibility to Dinoprostone; PTGER1 results in increased susceptibility to Dinoprostone
PTGER1 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased abundance of Inositol Phosphates; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of PRKACA protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Dinoprostone binds to and results in increased activity of PTGER1 protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein]
Dinoprostone results in increased activity of PTGER1 protein
CTD PMID:11375261, PMID:15126118, PMID:15311063, PMID:17408863, PMID:20335389, PMID:22188298 NCBI chr19:24,799,422...24,803,373
Ensembl chr19:24,800,072...24,803,373
JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions
increases activity
increases expression
ISO
EXP
[[Dinoprostone results in increased activity of PTGER2 protein] which results in increased susceptibility to nickel sulfate] which results in increased secretion of CXCL8 protein; [Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; [Dinoprostone results in increased activity of PTGER2 protein] which results in increased susceptibility to nickel sulfate; cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of PTGER2 protein]; Dinoprostone binds to and results in increased activity of PTGER2 protein; Dinoprostone inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of [PTGER2 protein co-treated with GLRA3 protein]]; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP]; PTGER2 protein promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein]
PTGER2 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]
CTD PMID:15131310, PMID:15930264, PMID:17408863, PMID:17709599, PMID:17761898, PMID:23526216, PMID:27636113, PMID:30208247 NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
JBrowse link
G Ptger3 prostaglandin E receptor 3 multiple interactions
increases expression
affects binding
increases activity
affects response to substance
ISO
EXP
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP; Dinoprostone binds to and results in increased activity of PTGER3 protein
Dinoprostone results in increased expression of PTGER3 mRNA
Dinoprostone binds to PTGER3 protein; Dinoprostone binds to PTGER3 protein alternative form
PTGER3 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER3 protein affects the reaction [Dinoprostone results in decreased transport of Calcium]
PTGER3 affects the susceptibility to Dinoprostone
CTD PMID:10357836, PMID:11375261, PMID:12535167, PMID:14636300, PMID:15937517, PMID:17242161, PMID:17408863 NCBI chr 2:263,895,093...263,979,682
Ensembl chr 2:263,895,241...263,979,698
JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions
increases expression
increases activity
ISO
EXP
Dinoprostone binds to and results in decreased activity of PTGER4 protein
Dinoprostone results in increased expression of PTGER4 protein
PTGER4 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]
Dinoprostone results in increased expression of PTGER4 mRNA
[[Dinoprostone results in increased activity of PTGER4 protein] which results in increased susceptibility to nickel sulfate] which results in increased secretion of CXCL8 protein; [Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; [Dinoprostone results in increased activity of PTGER4 protein] which results in increased susceptibility to nickel sulfate; cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of PTGER4 protein]; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP]
CTD PMID:10800959, PMID:12009843, PMID:17408863, PMID:23526216, PMID:30208247 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
G Ptges prostaglandin E synthase increases abundance
multiple interactions
ISO
EXP
PTGES results in increased abundance of Dinoprostone
[Diclofenac results in decreased expression of PTGES mRNA] which results in decreased abundance of Dinoprostone
[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone; [Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone; cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]; HIF1A protein promotes the reaction [[Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]]
[GPX2 protein affects the expression of PTGES protein] which affects the metabolism of Dinoprostone; [IL6 protein results in increased expression of PTGES mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [Lithium Chloride results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone; [Tetrachlorodibenzodioxin results in increased expression of PTGES mRNA] which results in increased chemical synthesis of Dinoprostone; PTGES protein affects the reaction [Tetrachlorodibenzodioxin results in increased abundance of Dinoprostone]
CTD PMID:17369862, PMID:18479189, PMID:19393675, PMID:19428335, PMID:19692487, PMID:20042640, PMID:22430074, PMID:24285838 NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
JBrowse link
G Ptges2 prostaglandin E synthase 2 multiple interactions ISO
EXP
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Lipopolysaccharides results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Lipopolysaccharides results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone; PTGES2 promotes the reaction [APP protein modified form results in increased abundance of Dinoprostone]
CTD PMID:19934399, PMID:20171164 NCBI chr 3:11,424,195...11,431,379
Ensembl chr 3:11,424,099...11,431,402
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions
increases chemical synthesis
ISO
EXP
Indomethacin inhibits the reaction [PTGS1 protein results in increased chemical synthesis of Dinoprostone]; PTGS1 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]
[resveratrol results in decreased activity of PTGS1 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]]; [SC 560 results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; Dinoprostone results in decreased susceptibility to [resveratrol results in decreased activity of PTGS1 protein]
[mofezolac results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; [resveratrol results in decreased activity of PTGS1 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of OSMR mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT3 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CEBPA protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of GPX1 mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP8 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased degradation of and results in decreased expression of NFKBIA protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BAK1 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of CCL2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of FASL protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of TNF protein]]
CTD PMID:10594344, PMID:16354411, PMID:16894348, PMID:19066340, PMID:19751497, PMID:21873648, PMID:25432964, PMID:27050768 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases chemical synthesis
multiple interactions
affects abundance
increases expression
increases abundance
ISO
EXP
PTGS2 protein results in increased chemical synthesis of Dinoprostone
1-phenyl-6,7-dihydroxy-isochroman inhibits the reaction [[Lipopolysaccharides results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 2,2'-azobis(2-amidinopropane) promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; 3,4-dihydroxyphenylethanol inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased abundance of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [[Oligomycins co-treated with IL1B protein] results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [amentoflavone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [baohuoside I results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone; [Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone; [Celecoxib analog results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [cumene hydroperoxide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Dronabinol results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Etodolac results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Fluorouracil results in increased expression of PTGS2 protein] which results in increased abundance of and results in increased secretion of Dinoprostone; [Genistein inhibits the reaction [Fluorouracil results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [Hydrogen Peroxide results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of and results in increased secretion of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Melitten results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Meloxicam results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [nickel sulfate co-treated with Dinoprostone] results in increased expression of PTGS2 protein; [nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Particulate Matter results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; [PRODH results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone; [PSEN2 protein mutant form results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [PTGS2 co-treated with Dinoprostone] results in increased expression of VEGFA; [PTGS2 protein results in increased chemical synthesis of Dinoprostone] which results in decreased susceptibility to Fenretinide; [PTGS2 protein results in increased chemical synthesis of Dinoprostone] which results in decreased susceptibility to Tamoxifen; [rofecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [SC 791 results in decreased activity of PTGS2 protein] inhibits the reaction [cholesterol-3-beta,5-alpha, 6-beta-triol results in increased abundance of Dinoprostone]; [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [TGFB1 results in increased expression of PTGS2] which results in increased abundance of Dinoprostone; [TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone; [Vehicle Emissions results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; acadesine inhibits the reaction [[Fluorouracil results in increased expression of PTGS2 protein] which results in increased abundance of and results in increased secretion of Dinoprostone]; arzanol inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Celecoxib inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [[Particulate Matter results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [[Vehicle Emissions results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]; Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]]; Etodolac inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]; Histamine promotes the reaction [[TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone]; Ibuprofen inhibits the reaction [PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]; Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]; Ketoprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; lucidone inhibits the reaction [2,2'-azobis(2-amidinopropane) promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; manoalide inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; nimesulide inhibits the reaction [PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone]; oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone; PTGS2 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; SB 203580 inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; scalaradial inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]]; trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]
[DuP 697 results in decreased expression of PTGS2] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of Dinoprostone]; [HCRT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprostone; [nimesulide results in decreased expression of PTGS2 protein] which results in decreased abundance of Dinoprostone; [o,p'-DDT results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprostone; [PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [rofecoxib results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]]; [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [Indomethacin results in increased expression of PTGS2]; Dinoprostone results in decreased susceptibility to [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein]; Dinoprostone results in decreased susceptibility to [rofecoxib results in decreased activity of PTGS2 protein]; endotoxin, Escherichia coli promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Ibuprofen inhibits the reaction [endotoxin, Escherichia coli promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Ibuprofen inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; IL1B protein promotes the reaction [PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Meloxicam inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone; pyrrolidine dithiocarbamic acid inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Troglitazone inhibits the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; wuzi yanzong analog inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]
PTGS2 protein affects the abundance of Dinoprostone metabolite
Dinoprostone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone results in increased expression of PTGS2 mRNA; Dinoprostone results in increased expression of PTGS2 protein
PTGS2 protein mutant form results in increased abundance of Dinoprostone metabolite; PTGS2 protein results in increased abundance of Dinoprostone
[Thiamine deficiency results in increased expression of PTGS2 mRNA] which results in increased expression of Dinoprostone
3-caffeoyl-4-dicaffeoylquinic acid inhibits the reaction [phorbolol myristate acetate promotes the reaction [PTGS2 protein results in increased abundance of Dinoprostone]]; 4-hydroxyphenylethanol inhibits the reaction [[Lipids results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [[Aspirin co-treated with Hydrochloric Acid] results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [[nimesulide results in decreased activity of PTGS2 protein] co-treated with [GW0742 binds to and results in increased activity of PPARD protein]] results in decreased abundance of Dinoprostone; [Acetaminophen results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [Cadmium results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Cadmium results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [GPX2 protein affects the activity of PTGS2 protein] which affects the metabolism of Dinoprostone; [IL6 protein results in increased expression of PTGS2 mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [KT 5720 co-treated with Dinoprostone] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; [Lipids results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; [Melitten results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Mycoplasma arthritidis mitogen results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [nonylphenol results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [prunetin results in decreased expression of PTGS2 mRNA] which results in decreased chemical synthesis of Dinoprostone; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprostone; [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [sulindac sulfone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Zymosan results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; Acetylcysteine inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Caffeine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Capsaicin inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; capsazepine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Carthamus yellow inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased expression of BIRC5 protein]; Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased phosphorylation of STAT3 protein]; Dinoprostone inhibits the reaction [copper protoporphyrin IX inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Drugs, Chinese Herbal inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone]; flavokawain A inhibits the reaction [Lipopolysaccharides promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Flurbiprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; IL17RA gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [[soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; Lipopolysaccharides promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; nimesulide inhibits the reaction [[soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; phorbolol myristate acetate promotes the reaction [PTGS2 protein results in increased abundance of Dinoprostone]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; PPARD protein affects the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; PPARD protein mutant form inhibits the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipids results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Selenium deficiency promotes the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; withaferin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]
CTD PMID:7575673, PMID:8621535, PMID:8662662, PMID:9266823, PMID:9321948, PMID:9576062, PMID:9705326, PMID:10491155, PMID:10594344, PMID:10791687, PMID:11094054, PMID:11095985, PMID:11112151, PMID:11118042, PMID:11133817, PMID:11286988, PMID:11405284, PMID:11454666, PMID:11500931, PMID:11527419, PMID:11530235, PMID:11743745, PMID:11821123, PMID:11854442, PMID:11882577, PMID:11978490, PMID:11997384, PMID:12144868, PMID:12164941, PMID:12417326, PMID:12517972, PMID:12757841, PMID:12821125, PMID:14530214, PMID:14687664, PMID:14972014, PMID:14984594, PMID:15212812, PMID:15236176, PMID:15242784, PMID:15529353, PMID:15753380, PMID:15878913, PMID:15896711, PMID:16004971, PMID:16127422, PMID:16194365, PMID:16325209, PMID:16331303, PMID:16396944, PMID:16489006, PMID:16529823, PMID:16777358, PMID:16804302, PMID:16894348, PMID:16997862, PMID:17067557, PMID:17570326, PMID:17651055, PMID:17767925, PMID:18081942, PMID:18165598, PMID:18187276, PMID:18297109, PMID:18305957, PMID:18378017, PMID:18479189, PMID:18481165, PMID:18485224, PMID:18507870, PMID:18759268, PMID:18794809, PMID:18805435, PMID:18832182, PMID:18834901, PMID:18840457, PMID:19289254, PMID:19397918, PMID:19428335, PMID:19616084, PMID:19748995, PMID:19751497, PMID:19758985, PMID:19931518, PMID:19954759, PMID:20040740, PMID:20558268, PMID:20678559, PMID:20737476, PMID:20844277, PMID:20848677, PMID:20850495, PMID:20933508, PMID:20954072, PMID:21147091, PMID:21177414, PMID:21268125, PMID:21269535, PMID:21396905, PMID:21873648, PMID:21893401, PMID:21911040, PMID:21913898, PMID:22101131, PMID:22306367, PMID:22359662, PMID:22542552, PMID:22549761, PMID:22595400, PMID:22771391, PMID:22974838, PMID:23110475, PMID:23209616, PMID:23597450, PMID:23712098, PMID:23727179, PMID:24003391, PMID:24161485, PMID:24285838, PMID:25432964, PMID:26464283, PMID:27050768 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein]
Dinoprostone inhibits the reaction [copper protoporphyrin IX inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]; Dinoprostone promotes the reaction [Lipopolysaccharides affects the localization of RELA protein]
CTD PMID:22188298, PMID:24003391 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Ren renin multiple interactions ISO [Sodium, Dietary deficiency results in increased susceptibility to Dinoprostone] which results in increased secretion of REN protein CTD PMID:10432392 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Retn resistin increases secretion ISO RETN protein results in increased secretion of Dinoprostone CTD PMID:23827175 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Rorc RAR-related orphan receptor C increases expression
multiple interactions
ISO Dinoprostone results in increased expression of RORC
Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA]
CTD PMID:19273625 NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein]; wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein] CTD PMID:20335389 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO Dinoprostone results in increased expression of RUNX2 mRNA; Dinoprostone results in increased expression of RUNX2 protein CTD PMID:27050768 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
ISO Dinoprostone inhibits the reaction [SIRT1 mutant form promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]]
Dinoprostone results in decreased expression of SIRT1 mRNA; Dinoprostone results in decreased expression of SIRT1 protein
1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acid inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; 4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; ATF3 protein affects the reaction [Dinoprostone results in decreased expression of SIRT1 mRNA]; Dinoprostone promotes the reaction [ATF3 protein binds to SIRT1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]]
CTD PMID:20335659, PMID:20844277, PMID:23257246, PMID:30409902 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Slc16a3 solute carrier family 16 member 3 multiple interactions ISO Dinoprostone promotes the reaction [nickel chloride results in increased expression of SLC16A3 mRNA] CTD PMID:27452194 NCBI chr10:110,138,519...110,148,360
Ensembl chr10:110,138,586...110,148,358
JBrowse link
G Slc22a6 solute carrier family 22 member 6 decreases expression EXP Dinoprostone results in decreased expression of SLC22A6 protein CTD PMID:19605544 NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
JBrowse link
G Slc22a7 solute carrier family 22 member 7 increases transport
increases uptake
ISO SLC22A7 protein results in increased transport of Dinoprostone
SLC22A7 protein results in increased uptake of Dinoprostone
CTD PMID:12065749, PMID:15901346 NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
JBrowse link
G Slc22a8 solute carrier family 22 member 8 increases transport
decreases expression
affects transport
ISO
EXP
SLC22A8 protein results in increased transport of Dinoprostone
Dinoprostone results in decreased expression of SLC22A8 protein
SLC22A8 protein affects the transport of Dinoprostone
CTD PMID:11306713, PMID:15100168, PMID:19605544 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions
increases expression
ISO Dinoprostone promotes the reaction [nickel chloride results in increased expression of SLC2A1 mRNA]
Dinoprostone results in increased expression of SLC2A1 mRNA
CTD PMID:27452194 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
JBrowse link
G Slco2a1 solute carrier organic anion transporter family, member 2a1 multiple interactions
increases transport
ISO Diclofenac inhibits the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Indomethacin promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Ketoprofen promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; lumiracoxib inhibits the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Naproxen promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone] CTD PMID:19843975 NCBI chr 8:111,495,443...111,577,320
Ensembl chr 8:111,495,331...111,577,833
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO SOD2 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone] CTD PMID:14514642 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [Arsenic Trioxide results in increased expression of SOX2 protein]] CTD PMID:29396848 NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
JBrowse link
G Sox9 SRY-box transcription factor 9 increases expression ISO Dinoprostone results in increased expression of SOX9 mRNA; Dinoprostone results in increased expression of SOX9 protein CTD PMID:27050768 NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
decreases expression
ISO Dinoprostone inhibits the reaction [NR2F2 protein binds to STAR promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to STAR promoter]; Dinoprostone promotes the reaction [NR5A1 protein binds to STAR promoter]
Dinoprostone results in increased expression of STAR mRNA; Dinoprostone results in increased expression of STAR protein
Dinoprostone results in decreased expression of STAR mRNA
CTD PMID:19001523, PMID:19253104 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased phosphorylation of STAT3 protein]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT3 protein]] CTD PMID:21268125, PMID:25432964 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions EXP Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Dinoprostone promotes the reaction [Kallidin results in increased secretion of TAC1 protein]; Dinoprostone promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine] CTD PMID:11166334, PMID:16039053, PMID:18234883 NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
JBrowse link
G Tbx21 T-box transcription factor 21 decreases expression ISO Dinoprostone results in decreased expression of TBX21 mRNA CTD PMID:19273625 NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331
JBrowse link
G Tfrc transferrin receptor decreases expression ISO Dinoprostone results in decreased expression of TFRC protein CTD PMID:2989362 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
ISO
EXP
[TGFB1 results in increased expression of PTGS2] which results in increased abundance of Dinoprostone
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]
Dinoprostone results in decreased expression of TGFB1 mRNA
Dinoprostone inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA]
CTD PMID:8877289, PMID:16489006, PMID:28434932 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA] CTD PMID:28434932 NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
JBrowse link
G Tgfb3 transforming growth factor, beta 3 multiple interactions ISO CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] CTD PMID:28434932 NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 multiple interactions ISO [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA] CTD PMID:28434932 NCBI chr 5:63,056,071...63,119,635
Ensembl chr 5:63,050,758...63,119,635
JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 multiple interactions ISO [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA] CTD PMID:28434932 NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
JBrowse link
G Thrsp thyroid hormone responsive decreases expression ISO Dinoprostone results in decreased expression of THRSP mRNA CTD PMID:10357836 NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression
multiple interactions
ISO Dinoprostone results in increased expression of TIMP1 mRNA; Dinoprostone results in increased expression of TIMP1 protein
Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]]
CTD PMID:16330497, PMID:25432964 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions ISO [TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone; Histamine promotes the reaction [[TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone] CTD PMID:20040740 NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases secretion
increases abundance
decreases expression
ISO
EXP
1-carboxyheptylimidazole promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; [Triclosan co-treated with Cetylpyridinium] inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; cyanidin 3-O-glucoside inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; Dinoprostone inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Ketoconazole promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; pyrrolidine dithiocarbamic acid promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]]; sorbinil inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Terbinafine promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; Triclosan inhibits the reaction [TNF protein results in increased metabolism of Dinoprostone]; Triclosan inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; wedelolactone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]
TNF protein results in increased abundance of Dinoprostone; TNF protein results in increased abundance of Dinoprostone metabolite
Dinoprostone results in decreased expression of TNF protein
Benzo(a)pyrene promotes the reaction [TNF protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone metabolite]; Dexamethasone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; TNF protein promotes the reaction [Benzo(a)pyrene results in increased abundance of Dinoprostone]
[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Curcumin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Curcumin inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of TNF protein]]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Dinoprostone inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; Dinoprostone inhibits the reaction [Zymosan results in increased expression of TNF protein]; Melitten inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]
TNF protein results in increased abundance of Dinoprostone; TNF results in increased abundance of Dinoprostone
CTD PMID:1515551, PMID:1993070, PMID:7536779, PMID:9298541, PMID:9576062, PMID:10495789, PMID:10614771, PMID:11301049, PMID:12743569, PMID:14623498, PMID:15379866, PMID:15489888, PMID:15642051, PMID:16253096, PMID:16303787, PMID:16492401, PMID:16754782, PMID:16784723, PMID:17067557, PMID:18054255, PMID:18952292, PMID:19616084, PMID:20388727, PMID:21334316, PMID:21745554, PMID:21803157, PMID:21913898, PMID:22039321, PMID:23257246, PMID:25432964, PMID:25866079, PMID:27793764, PMID:32613688 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B multiple interactions
increases secretion
increases expression
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]
Dinoprostone results in increased expression of TNFRSF11B mRNA
CTD PMID:25234201 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A increases activity ISO Dinoprostone results in increased activity of TNFRSF1A protein CTD PMID:19407222 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
G Trpc7 transient receptor potential cation channel, subfamily C, member 7 increases response to substance ISO TRPC7 results in increased susceptibility to Dinoprostone CTD PMID:16790996 NCBI chr17:8,134,267...8,280,360
Ensembl chr17:8,135,251...8,279,515
JBrowse link
G Trpv4 transient receptor potential cation channel, subfamily V, member 4 multiple interactions ISO TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]] CTD PMID:18234883 NCBI chr12:47,698,915...47,737,902
Ensembl chr12:47,698,947...47,737,902
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions EXP UCP1 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone] CTD PMID:14514642 NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases chemical synthesis EXP UGT1A1 protein mutant form results in increased chemical synthesis of Dinoprostone CTD PMID:3864191 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Vasp vasodilator-stimulated phosphoprotein increases phosphorylation ISO Dinoprostone results in increased phosphorylation of VASP protein CTD PMID:18182247 NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO [[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [nickel sulfate co-treated with Dinoprostone] results in increased secretion of VEGFA protein; [PTGS2 co-treated with Dinoprostone] results in increased expression of VEGFA CTD PMID:12821125, PMID:18832182, PMID:21681689 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vegfc vascular endothelial growth factor C decreases expression ISO Dinoprostone results in decreased expression of VEGFC mRNA; Dinoprostone results in decreased expression of VEGFC protein CTD PMID:18509974 NCBI chr16:40,440,371...40,555,178
Ensembl chr16:40,440,207...40,555,576
JBrowse link
G Vgf VGF nerve growth factor inducible increases abundance EXP VGF results in increased abundance of Dinoprostone CTD PMID:20805684 NCBI chr12:22,677,302...22,680,630
Ensembl chr12:22,677,607...22,680,630
JBrowse link
G Wt1 WT1 transcription factor multiple interactions ISO Dinoprostone inhibits the reaction [WT1 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to STAR promoter] CTD PMID:19001523 NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
JBrowse link
13,14-dihydro-15-oxo-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgr1 prostaglandin reductase 1 increases abundance
multiple interactions
ISO PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
CTD PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
15-dehydro-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases chemical synthesis ISO HPGD protein results in increased chemical synthesis of 15-ketoprostaglandin E2 CTD PMID:20448048 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions
increases metabolic processing
increases reduction
EXP
ISO
15-ketoprostaglandin E2 inhibits the reaction [PTGR1 protein results in increased reduction of 10-nitro-oleic acid analog]; Dithionitrobenzoic Acid inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]; Indomethacin inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
CTD PMID:23878198, PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
8-epi-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptger4 prostaglandin E receptor 4 affects response to substance ISO PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 CTD PMID:22565502 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      application 19391
        pharmaceutical 19272
          drug 19272
            oxytocic 244
              prostaglandin E2 230
                13,14-dihydro-15-oxo-prostaglandin E2 1
                15-dehydro-prostaglandin E2 2
                2-[(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl]-sn-glycero-3-phosphocholine 0
                2-[(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl]-sn-glycero-3-phosphoethanolamine 0
                20-hydroxyprostaglandin E2 0
                8-epi-prostaglandin E2 1
                nitroproston 0
                prostaglandin E2 1-glyceryl ester 0
                prostaglandin E2 2-glyceryl ester 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      carboxylic acid 18060
                                        monocarboxylic acid 17406
                                          fatty acid 15844
                                            fatty acid derivative 1021
                                              icosanoid 453
                                                prostanoid 395
                                                  prostaglandin 390
                                                    prostaglandins E 233
                                                      prostaglandin E2 230
                                                        13,14-dihydro-15-oxo-prostaglandin E2 1
                                                        15-dehydro-prostaglandin E2 2
                                                        2-[(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl]-sn-glycero-3-phosphocholine 0
                                                        2-[(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl]-sn-glycero-3-phosphoethanolamine 0
                                                        20-hydroxyprostaglandin E2 0
                                                        8-epi-prostaglandin E2 1
                                                        nitroproston 0
                                                        prostaglandin E2 1-glyceryl ester 0
                                                        prostaglandin E2 2-glyceryl ester 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.